XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 9 months ended Sep. 30, 2016 - USD ($)
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Common Stock [Member]
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Retained Earnings [Member]
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Treasury Stock [Member]
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
AOCI Attributable to Parent [Member]
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Conversion of Bridge Loan to Common Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Conversion of Bridge Loan to Common Stock [Member]
Common Stock [Member]
Conversion of Bridge Loan to Common Stock [Member]
Additional Paid-in Capital [Member]
Conversion of Bridge Loan to Common Stock [Member]
Retained Earnings [Member]
Conversion of Bridge Loan to Common Stock [Member]
Treasury Stock [Member]
Conversion of Bridge Loan to Common Stock [Member]
AOCI Attributable to Parent [Member]
Conversion of Bridge Loan to Common Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock [Member]
AOCI Attributable to Parent [Member]
Total
BALANCE (in shares) at Dec. 31, 2015                             7,612,838     (1,000,000)    
BALANCE at Dec. 31, 2015                             $ 761 $ 5,886,971 $ (6,306,297) $ (100,000) $ (148,651) $ (667,216)
Atrinsic shares converted (in shares)                             297,468 25,867        
Atrinsic shares converted                             $ 1 $ 3 63,381 63,385
Protagenic shares converted (in shares)                             6,612,838 (7,612,838)     1,000,000    
Protagenic shares converted                             $ 6 $ (761) (99,245) $ 100,000
Warrants issued for exchange of debt                             340,784 340,784
Stock Issued During Period, Shares, New Issues                             4,108,460        
Stock Issued During Period, Value, New Issues                             $ 4 4,761,793 4,761,797
Warrants issued to placement agent                             146,641 146,641
Reclassification of warrants to derivative liability                             (487,425) (487,425)
Foreign currency translation (loss)                             (25,457) (25,457)
Stock compensation - stock options                             450,566 450,566
Conversion of Convertible Securities (in shares) (8,221,837) 8,221,837         60,211                      
Conversion of Convertible Securities $ (8) $ 822 $ (814) $ 6 $ 75,259 $ 75,265              
Net loss                             (1,719,749) (1,719,749)
BALANCE (in shares) at Sep. 30, 2016                             2,796,929 8,307,915        
BALANCE at Sep. 30, 2016                             $ 3 $ 831 $ 11,137,911 $ (8,026,046) $ (174,108) $ 2,938,591